HOME >> BIOLOGY >> NEWS
Paratek Pharmaceuticals presents multiple sclerosis data at Society for Neuroscience annual meeting

Paratek Pharmaceuticals, Inc. announced results of preclinical studies demonstrating that a new class of compounds, orally available non-antibacterial tetracyclines, has shown promising activity in a preclinical animal model of multiple sclerosis (MS). Affecting approximately two million people worldwide, MS is a chronic, inflammatory condition of the nervous system and the most common, non-traumatic, neurological disease in young adults. Dr. David McKenney, a Paratek scientist, will present the findings during an oral presentation at 2:30 p.m. PST (5:30 p.m. EST) today at Neuroscience 2004, the Society for Neuroscience's 34th Annual Meeting in San Diego.

For the first time, Paratek is presenting data showing that its non-antibacterial tetracycline compounds in a preclinical model of MS have efficacy comparable to minocycline, an antibiotic also in the tetracycline family. A previous clinical study directed by Dr. Luanne Metz at the University of Calgary has demonstrated disease protection in MS patients treated with minocycline. Unfortunately, long-term treatment with minocycline or any other broad-spectrum antibiotics causes many patients to experience intolerability related to antibiotic side effects. In today's presentation, Paratek will report that three non-antibacterial tetracycline compounds, with different structures, demonstrated activity in reducing limb paralysis in the preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS. These compounds have no detectable antibacterial activity.

Paratek Pharmaceuticals, Inc. and Serono (virt-x: SEO and NYSE: SRA) announced today that they have entered into an agreement to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS). The agreement covers the compounds for which Dr. McKenney presents data today.

Stuart Levy, Paratek's Vice Chairman, Chief Scientific Officer and Co-Founder, commented, "The clinica
'"/>

Contact: Katie Compa
kcompa@burnsmc.com
212-213-0006
Burns McClellan
27-Oct-2004


Page: 1 2

Related biology news :

1. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels
2. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
3. SNM presents awards on Capitol Hill
4. ESA presents the sharpest ever satellite map of Earth
5. New book presents neurobiology from an evolutionary perspective
6. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
7. Childrens Hospital and Research Center-Oakland presents a new maternal diet study
8. USGS presents a world of science at GSA in Philadelphia
9. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference
10. DFG presents the 2006 MAK and BAT value list
11. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... May 17, 2017 , ... ... today that their Chief Executive Officer, Maik Jornitz, was recognized as a Top ... Power List celebrates 100 individuals “involved in bettering the pharma industry and bringing ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... When James Sherley, was notified earlier this ... Most Valuable Brands for the Year 2017 by The Silicon Review , he was ... making good progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... Hi-C metagenomic deconvolution service. ProxiMeta enables researchers to obtain complete, distinct genomes ... insights at lower cost. , “We’re very excited about the commercial launch ...
(Date:5/16/2017)... CA (PRWEB) , ... May 16, 2017 , ... ... medicine technology and cancer diagnostics, has released its ClearID Lung Cancer blood test. ... in lung cancer, this new test is designed to quickly and accurately identify ...
Breaking Biology Technology:
Cached News: